@phdthesis{Emmert2010,
  author    = {Emmert, Wulf-Kristian},
  title     = {Rachitis-{\"a}hnliche Symptome bei nigerianischen Kindern aus der Ethnie der Gbagyi in der s{\"u}dwestlichen Region Kadunas: Identifizierung des biochemischen Defekts, Sammeln von epidemiologischen Daten und Beschreibung des klinischen Bildes},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-48354},
  school      = {Universit{\"a}t W{\"u}rzburg},
  year      = {2010},
  abstract  = {Zielsetzung: In einer Population im Westen der nigerianischen Stadt Kaduna wurden seit 20-30 Jahren vermehrt Kinder mit einer deformierenden Knochenerkrankung registriert. Ziel der Studie war, eine Diagnose zu stellen und Risikofaktoren f{\"u}r die Erkrankung zu identifizieren. Studiendesign: 26 Familien aus 20 D{\"o}rfern wurden in die Studie einbezogen. In einer nicht-randomisierten Fall-Kontroll-Studie wurden 53 erkrankte Kinder mit 48 gesunden sowie 16 fraglich erkrankten Geschwistern anhand ihrer Ergebnisse aus Anamnese, klinischer Untersuchung und Laborchemie miteinander verglichen. Ebenfalls wurden Daten von 24 V{\"a}tern und 36 M{\"u}ttern ausgewertet. Weitere Untersuchungen umfassten Ern{\"a}hrung, Anthropometrie, Umweltfaktoren und Genetik der teilnehmenden Familien. Ergebnisse: Die betroffenen Kinder wiesen deutliche Rachitissymptome auf, bei allen lag eine Kalzium-defiziente Rachitis vor. Zwischen den Laborergebnissen von Fall- und Kontrollgruppe bestanden signifikante Unterschiede, nicht jedoch zwischen der Gruppe der fraglichen F{\"a}lle und der Kontrollgruppe. In der Fallgruppe waren die Serumspiegel von Kalzium und 25-Vit. D signifikant niedriger, die Serumspiegel von 1,25-Vit. D, ALP und PTH signifikant h{\"o}her als in der Kontrollgruppe. Bei den Eltern zeigten die M{\"u}tter insbesondere in der Stillzeit signifikant niedrigere Kalzium- und signifikant h{\"o}here 1,25- Vit. D- und PTH-Serumspiegel als die V{\"a}ter. Als Ursache f{\"u}r den Kalziummangel der Studienteilnehmer konnte eine kalziumarme und phytatreiche Di{\"a}t der Familien identifiziert werden. Hinweise auf einen gesunkenen Lebensstandard und eine Abnahme der Bodenqualit{\"a}t erkl{\"a}ren die in den letzten Jahrzehnten stark gestiegene Pr{\"a}valenz der Erkrankung. Bei weitgehend gleichen Ern{\"a}hrungs- und Umweltfaktoren innerhalb einer Familie konnten keine individuellen Faktoren identifiziert werden, die bei einzelnen Familienmitgliedern zum Ausbruch der Erkrankung f{\"u}hrten. Trotz einzelner Hinweise auf eine m{\"o}gliche genetische Pr{\"a}disposition war kein einheitliches Vererbungsmuster in den Stammb{\"a}umen der Familien erkennbar. Schlussfolgerung: Neben dem Hauptfaktor einer kalziumarmen Ern{\"a}hrung m{\"u}ssen weitere Faktoren f{\"u}r eine Kalzium-defiziente Rachitis vorliegen. Mehrere Hinweise deuten auf eine multifaktorielle Genese der Erkrankung hin. Die noch offenstehenden Fragen sollten durch weitere Studien gekl{\"a}rt werden, um die richtigen Maßnahmen f{\"u}r Pr{\"a}vention und Therapie zu treffen.},
  subject      = {Rachitis},
  language  = {de}
}
@article{VogtGirschickSchweitzeretal.2020,
  author    = {Vogt, Marius and Girschick, Hermann and Schweitzer, Tilmann and Benoit, Clemens and Holl-Wieden, Annette and Seefried, Lothar and Jakob, Franz and Hofmann, Christine},
  title     = {Pediatric hypophosphatasia: lessons learned from a retrospective single-center chart review of 50 children},
  series = {Orphanet Journal of Rare Diseases},
  volume    = {15},
  journal   = {Orphanet Journal of Rare Diseases},
  doi       = {10.1186/s13023-020-01500-x},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-230505},
  year      = {2020},
  abstract  = {Background Hypophosphatasia (HPP) is a rare, inherited metabolic disorder caused by loss-of-function mutations in the ALPL gene that encodes the tissue-nonspecific alkaline phosphatase TNAP (ORPHA 436). Its clinical presentation is highly heterogeneous with a remarkably wide-ranging severity. HPP affects patients of all ages. In children HPP-related musculoskeletal symptoms may mimic rheumatologic conditions and diagnosis is often difficult and delayed. To improve the understanding of HPP in children and in order to shorten the diagnostic time span in the future we studied the natural history of the disease in our large cohort of pediatric patients. This single centre retrospective chart review included longitudinal data from 50 patients with HPP diagnosed and followed at the University Children's Hospital Wuerzburg, Germany over the last 25 years. Results The cohort comprises 4 (8\%) perinatal, 17 (34\%) infantile and 29 (58\%) childhood onset HPP patients. Two patients were deceased at the time of data collection. Diagnosis was based on available characteristic clinical symptoms (in 88\%), low alkaline phosphatase (AP) activity (in 96\%), accumulating substrates of AP (in 58\%) and X-ray findings (in 48\%). Genetic analysis was performed in 48 patients (31 compound heterozygous, 15 heterozygous, 2 homozygous mutations per patient), allowing investigations on genotype-phenotype correlations. Based on anamnestic data, median age at first clinical symptoms was 3.5 months (min. 0, max. 107), while median time to diagnosis was 13 months (min. 0, max. 103). Common symptoms included: impairment of motor skills (78\%), impairment of mineralization (72\%), premature loss of teeth (64\%), musculoskeletal pain and craniosynostosis (each 64\%) and failure to thrive (62\%). Up to now 20 patients started medical treatment with Asfotase alfa. Conclusions Reported findings support the clinical perception of HPP being a chronic multi-systemic disease with often delayed diagnosis. Our natural history information provides detailed insights into the prevalence of different symptoms, which can help to improve and shorten diagnostics and thereby lead to an optimised medical care, especially with promising therapeutic options such as enzyme-replacement-therapy with Asfotase alfa in mind.},
  language  = {en}
}
@article{DrechslerKolleritzMeinitzeretal.2013,
  author    = {Drechsler, Christiane and Kolleritz, Barbara and Meinitzer, Andreas and M{\"a}rz, Winfried and Ritz, Eberhard and K{\"o}nig, Paul and Neyer, Ulrich and Pilz, Stefan and Wanner, Christoph and Kronenberg, Florian},
  title     = {Homoarginine and Progression of Chronic Kidney Disease: Results from the Mild to Moderate Kidney Disease Study},
  series = {PLoS ONE},
  volume    = {8},
  journal   = {PLoS ONE},
  number    = {5},
  organization    = {MMKD Study Group},
  doi       = {10.1371/journal.pone.0063560},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-130979},
  pages     = {e63560},
  year      = {2013},
  abstract  = {Background: Homoarginine is an amino acid derivative mainly synthesized in the kidney. It is suggested to increase nitric oxide availability, enhance endothelial function and to protect against cardiovascular diseases. We aimed to investigate the relation between homoarginine, kidney function and progression of chronic kidney disease (CKD). Methods: We measured plasma homoarginine concentrations in baseline samples of the Mild to Moderate Kidney Disease (MMKD) Study, a prospective cohort study of 227 patients with CKD in Europe. Homoarginine concentrations were available in 182 of the baseline samples and in 139 of the prospectively-followed patients. We correlated homoarginine concentrations to parameters of kidney function. The association between homoarginine and progression of CKD was assessed during a follow-up of up to seven years (median 4.45 years, interquartile range 2.54-5.19) using Cox regression analysis. Progression of CKD was defined as doubling of baseline serum creatinine and/or end-stage renal disease. Results: Study participants were at baseline on average 47 \(\pm\)13 years old and 65\% were male. Mean \(\pm\) standard deviation of homoarginine concentrations were \(2.5 \pm 1.1 \mu mol/L\) and concentrations were incrementally lower at lower levels of GFR with mean concentrations of \(2.90 \pm 1.02 \mu mol/L\) (GFR. 90 ml/min), \(2.64 \pm 1.06 \mu mol/L\) (GFR 60-90 ml/min), \(2.52 \pm 1.24 \mu mol/L\) (GFR 30-60 ml/min) and \(2.05 \pm 0.78 \mu mol/L\) (GFR, 30 ml/min), respectively (p = 0.002). The age-and sex-adjusted risk to reach the renal endpoint was significantly higher by 62\% with each decrease by one standard deviation (\(1.1 \mu mol/L\)) of homoarginine (HR 1.62, 95\% CI 1.16-2.27, p = 0.005). This association was independent of proteinuria (HR 1.56, 95\% CI 1.11-2.20, p = 0.01), and was slightly attenuated when adjusting for GFR (HR 1.40 (95\% CI 0.98-1.98, p = 0.06). Conclusions: Homoarginine concentrations are directly correlated with kidney function and are significantly associated with the progression of CKD. Low homoarginine concentrations might be an early indicator of kidney failure and a potential target for the prevention of disease progression which needs further investigations.},
  language  = {en}
}
@article{SeefriedRakPetryketal.2021,
  author    = {Seefried, L. and Rak, D. and Petryk, A. and Genest, F.},
  title     = {Bone turnover and mineral metabolism in adult patients with hypophosphatasia treated with asfotase alfa},
  series = {Osteoporosis International},
  volume    = {32},
  journal   = {Osteoporosis International},
  number    = {12},
  doi       = {10.1007/s00198-021-06025-y},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-265310},
  pages     = {2505-2513},
  year      = {2021},
  abstract  = {Summary There is limited understanding of how asfotase alfa affects mineral metabolism and bone turnover in adults with pediatric-onset hypophosphatasia. This study showed that adults with hypophosphatasia treated with asfotase alfa experienced significant changes in biochemical markers of bone and mineral metabolism, possibly reflecting enhanced bone remodeling of previously osteomalacic bone. Introduction Hypophosphatasia (HPP), due to a tissue nonspecific alkaline phosphatase (TNSALP) deficiency, can cause impaired bone mineralization and turnover. Although HPP may be treated with asfotase alfa, an enzyme replacement therapy, limited data are available on how treatment with asfotase alfa affects mineral metabolism and bone turnover in adults with HPP. Methods ALP substrates, bone turnover and mineral metabolism markers, and bone mineral density (BMD) data from EmPATHY, a single-center, observational study of adults (≥ 18 years) with pediatric-onset HPP treated with asfotase alfa (NCT03418389), were collected during routine clinical care and analyzed from baseline through 24 months of treatment. Results Data from 21 patients showed significantly increased ALP activity and reduced urine phosphoethanolamine (PEA)/creatinine (Cr) ratios after baseline through 24 months of asfotase alfa treatment. There were significant transient increases in parathyroid hormone 1-84 (PTH), osteocalcin, and procollagen type 1 N-propeptide (P1NP) levels at 3 and 6 months and in tartrate-resistant acid phosphatase 5b (TRAP5b) levels at 3 months, with a significant decrease in N-terminal telopeptide of type 1 collagen (NTX) levels at 24 months. Lumbar spine BMD T scores continuously increased during treatment. Conclusion Significant changes in bone turnover and mineral metabolism markers after asfotase alfa treatment suggest that treatment-mediated mineralization may enable remodeling and bone turnover on previously unmineralized surfaces. Urine PEA/Cr ratios may be a useful parameter in monitoring treatment during routine care.},
  language  = {en}
}